AAV9 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| TR-987 | Z-101; GLYC-101; MG-3601 | Phase 3 Clinical | Kazia Therapeutics | Varicose Veins; Wounds and Injuries; Varicose Ulcer | Details |
| Monovalent norovirus Vaccine (Vaxart) | VXA-G1-1-NN; VXA-G1.1-NN | Phase 2 Clinical | Vaxart Inc | Norovirus Infections | Details |
| Poly ICLC (Oncovir) | Phase 2 Clinical | National Institutes Of Health, Oncovir Inc | Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Metastatic breast cancer; Lymphoma, T-Cell; Glioma; Carcinoma, Squamous Cell; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Lymphoma, B-Cell; Osteosarcoma; Urinary Bladder Neoplasms; Mesothelioma; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Glioblastoma; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; HIV Infections | Details | |
| BO-112 | BO-112 | Phase 2 Clinical | Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Colorectal Neoplasms; Neurofibrosarcoma; Sarcoma; Sarcoma, Synovial; Liposarcoma; Leiomyosarcoma; Dermatofibrosarcoma; Stomach Neoplasms; Histiocytoma, Malignant Fibrous; Retroperitoneal Neoplasms; Esophageal Neoplasms; Carcinoma, Basal Cell; Fibrosarcoma; Rhabdomyosarcoma | Details | |
| Monovalent norovirus Vaccine (Vaxart)/VXA-G2-4-NS | VXA-NVV-201 | Phase 2 Clinical | Vaxart Inc | Norovirus Infections | Details |
| CNTO-5 | CNTO-5 | Phase 1 Clinical | Inflammation | Details | |
| PGV-001 | PGV-001 | Phase 1 Clinical | Genentech Inc, Icahn School Of Medicine At Mount Sinai | Neoplasms; Urologic Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Rintatolimod | AMP-516; AMP-518 | Approved | Hemispherx Biopharma Inc | Rintamod, Ampligen | Argentina | Fatigue Syndrome, Chronic | Hemispherx Biopharma Inc | 2017-01-01 | HIV Infections; Ovarian Neoplasms; Pancreatic Neoplasms; Mesothelioma; Influenza, Human; Post-Acute COVID-19 Syndrome; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fatigue Syndrome, Chronic; HIV Seropositivity; Breast Neoplasms, Male | Details |